Inhibition of protein synthesis by imexon reduces HIF-1α expression in normoxic and hypoxic pancreatic cancer cells

Investigational New Drugs

Volumn 27, Issue 1, 2009, Pages 89-98

  Samulitis, Betty K ^a   Landowski, Terry H ^a   Dorr, Robert T ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Hypoxia; Imexon; Normoxia; Pancreas; Protein synthesis

Indexed keywords

CYSTEINE; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMEXON; INITIATION FACTOR 2ALPHA; METHIONINE; 4 IMINO 1,3 DIAZABICYCLO(3.1.0)HEXAN 2 ONE; 4-IMINO-1,3-DIAZABICYCLO(3.1.0)HEXAN-2-ONE; ALKANONE; DEOXYCYTIDINE; DRUG DERIVATIVE; ENZYME INHIBITOR; HIF1A PROTEIN, HUMAN; PROTEASOME; PROTEIN SYNTHESIS INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL HYPOXIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TRANSLATION REGULATION; CELL PROLIFERATION; METABOLISM; PANCREAS TUMOR; PHYSIOLOGY; TUMOR CELL LINE;

CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; ENZYME INHIBITORS; HEXANONES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PANCREATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SYNTHESIS INHIBITORS;

EID: 62749117614     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9149-9     Document Type: Article

References (49)

1. T Dragovich M Gordon D Mendeslon 2007 Phase I trial of imexon in patients with advanced malignancy J Clin Oncol 25 1779 1784 (Pubitemid 46797961)
2. Cohen SJ, Zalupski M, Modiano M, Conkling P, Patt Y, Davis P, Dorr R, Boytim M, Hersh E (2008) A phase I study of Amplimexon (AMP, imexon inj.) plus gemcitabine (Gem) as first line therapy in advanced pancreatic cancer (PC) with preclinical mechanistic study of dose limiting toxicity (DLT). Proceedings of the ASCO Annual Meeting
3. BS Iyengar RT Dorr WA Remers 2004 Chemical basis for the biological activity of imexon and related cyanoaziridines J Med Chem 47 218 223 (Pubitemid 38040505)
4. K Dvorakova CM Payne ME Tome MM Briehl T McClure RT Dorr 2000 Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon Biochem Pharmacol 60 749 758 (Pubitemid 30621659)
5. K Dvorakova CN Waltmire CM Payne ME Tome MM Briehl RT Dorr 2001 Induction of mitochondrial changes in myeloma cells by imexon Blood 97 3544 3551
6. K Dvorakova CM Payne TH Landowski ME Tome DS Halperin RT Dorr 2002 Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells Anticancer Drugs 13 1 13
7. RT Dorr MA Raymond TH Landowski NO Roman S Fukushima 2005 Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cells lines Int J Gastrointest Cancer 36 1 15 28 (Pubitemid 41443606)
8. EM Hersh CR Gschwind CW Taylor RT Dorr R Taetle SE Salmon 1992 Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro J Natl Cancer Inst 84 1238 1244
9. RC Wek HY Jiang TG Anthony 2006 Coping with stress: eIF2 kinases and translational control Biochem Soc Trans 34 Pt 1 7 11 (Pubitemid 43235522)
10. S Tan N Somia P Maher D Schubert 2001 Regulation of antioxidant metabolism by translation initiation factor 2 alpha J Cell Biol 152 997 1006 (Pubitemid 34286075)
11. HY Jiang RC Wek 2005 Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition J Biol Chem 280 14 14189 14202 (Pubitemid 40517321)
12. H Oettle D Arnold C Hempel H Riess 2000 The role of gemcitabine alone and in combination in the treatment of pancreatic cancer Anticancer Drugs 11 771 786
13. Poplin E, Levy DE, Berlin M (2006) Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). ASCO Proceedings 24(18s):180s
14. MJ Moore D Goldstein J Hamm 2007 Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) J Clin Oncol 25 15 1960 1966 (Pubitemid 46972777)
15. AM Senderowicz JR Johnson R Sridhara P Zimmerman R Justice R Pazdur 2007 Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas Oncology 21 1696 1706
16. AC Koong VK Mehta QT Le 2000 Pancreatic tumors show high levels of hypoxia Int J Radiat Oncol Biol Phys 48 919 922 (Pubitemid 30802127)
17. AJ Megibow 1992 Pancreatic adenocarcinoma: designing the examination to evaluate the clinical questions Radiology 183 297 303
18. JP Duffy G Eibl HA Reber OJ Hines 2003 Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer Mol Cancer 2 12
19. T Kitada S Seki H Sakaguchi T Sawada K Hirakawa K Wakasa 2003 Clinicopathological significance of hypoxia-inducible factor-1a expression in human pancreatic carcinoma Histopathology 43 550 555 (Pubitemid 38002343)
20. P Buchler HA Reber M Buchler 2003 Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer Pancreas 26 56 64 (Pubitemid 36020267)
21. N Akakura M Kobayashi I Horiuchi 2001 Constitutive expression of hypoxia-inducible factor-1a renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation Cancer Res 61 6548 6554 (Pubitemid 32783263)
22. SJ Welsh MY Koh G Powis 2006 The hypoxic inducible stress response as a target for cancer drug discovery Semin Oncol 33 486 497 (Pubitemid 44142742)
23. GL Semenza PH Roth HM Fang GL Wang 1994 Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1 J Biol Chem 269 23757 23763 (Pubitemid 24293585)
24. JM Brown 2002 Tumor microenvironment and the response to anticancer therapy Cancer Biol Ther 1 453 458
25. D Liao C Corle TN Seagroves RS Johnson 2007 Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression Cancer Res 67 563 572 (Pubitemid 46192193)
26. BA Teicher 1994 Hypoxia and drug resistance Cancer Metastasis Rev 13 139 168 (Pubitemid 24220002)
27. K Yokoi IJ Fidler 2004 Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine Clin Cancer Res 10 2299 2306 (Pubitemid 38445687)
28. A Sanjuan-Pla AM Cervera N Apostolova 2005 A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha FEBS Lett 579 2669 2674 (Pubitemid 40615675)
29. RD Guzy B Hoyos E Robin 2005 Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing Cell Metab 1 401 408 (Pubitemid 43960623)
30. NS Chandel DS McClintock CE Feliciano 2000 Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1a during hypoxia: a mechanism of 02 sensing J Biol Chem 275 25130 25138 (Pubitemid 30687005)
31. MC Simon 2006 Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization Adv Exp Med Biol 588 165 170
32. A Yunis GK Arimura DJ Russin 1977 Human pancreatic carcinoma (MiaPaCa-2) in continuous culture: sensitivity to asparaginase Int J Cancer 19 128 135 (Pubitemid 8016933)
33. M Lieber J Mazzetta W Nelson-Rees M Kaplan G Todaro 1975 Establishment of a continuous tumor-cell line (Panc-1) from a human carcinoma of the exocrine pancreas Int J Cancer 15 741 747
34. ES Lightcap TA McCormack CS Pien V Chau J Adams PJ Elliott 2000 Proteasome inhibition measurements: clinical application Clin Chem 46 673 683 (Pubitemid 30318423)
35. T Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 55 63 (Pubitemid 14203433)
36. KH Shain TH Landowski WS Dalton 2002 Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines J Immunol 168 2544 2553 (Pubitemid 34171863)
37. AF Kisselev AL Goldberg 2001 Proteasome inhibitors: from research tools to drug candidates Chem Biol 8 739 758 (Pubitemid 32752454)
38. GL Semenza 2003 Targeting HIF-1 for cancer therapy Cancer 3 721 732 (Pubitemid 37328811)
39. G Powis L Kirkpatrick 2004 Hypoxia inducible factor-1a as a cancer drug target Mol Cancer Ther 3 647 654 (Pubitemid 39193744)
40. NJ Mabjeesh DE Post MT Willard 2002 Geldanamycin induces degradation of hypoxia-inducible factor 1a protein via the proteosome pathway in prostate cancer cells Cancer Res 62 2478 2482 (Pubitemid 34462721)
41. H Chang KG Shyu CC Lee 2003 GL331 inhibits HIF-1a expression in a lung cancer model Biochem Biophys Res Commun 302 95 100 (Pubitemid 36268924)
42. YM Lee SH Kim HS Kim 2003 Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1a activity Biochem Biophys Res Commun 300 241 246 (Pubitemid 36042959)
43. VK Oliver AM Patton S Desai D Lorang SK Libutti EC Kohn 2003 Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole J Cell Physiol 197 139 148 (Pubitemid 37486236)
44. A Rapisarda B Uranchimerg O Sordet Y Pommier PH Shoemaker G Belillo 2004 Topoisomerase 1-mediated inhibition of hypoxia-inducible factor 1:mechanism and therapeutic implications Cancer Res 64 1475 1482 (Pubitemid 38235619)
45. H Zhong K Chiles D Feldser 2000 Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics Cancer Res 60 1541 1545 (Pubitemid 30183422)
46. Raijiman I, Levin B (1995) Exocrine tumors of pancreas. In: Haubrich WS, Schaffner F (eds) Bockus gastroentrology. 5th edn. Saunders, Philadelphia, pp 2984-3001
47. K Ranniger RM Saldino 1966 Arteriographic diagnosis of pancreas lesion Radiology 86 470 474
48. NA Yassa J Yang S Stein M Johnson P Ralls 1997 Gray-scale and color flow sonography of pancreatic ductal adenocarcinoma J Clin Ultrasound 25 473 470
49. J Scott RT Dorr B Samulitis TH Landowski 2007 Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines Cancer Chemother Pharmacol 59 749 757 (Pubitemid 46440597)